Business
Arno Therapeutics to Present Late-Breaking Abstract on AR-12 as Novel Therapeutic Candidate Against HIV Multidrug Resistant Strains at 15th European AIDS Conference
Arno Therapeutics to Present Late-Breaking Abstract on AR-12 as Novel Therapeutic Candidate Against HIV Multidrug Resistant Strains at 15th European AIDS Conference.
About this update from Arno Therapeutics Inc
[{"type":"text","content":"\nFLEMINGTON, N.J., Sept. 25, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced that a late-breaking abstract on AR-12 has been accepted for poster presentation at the upcoming 15th European AIDS Conference, hosted by the European AIDS Clinical Society (EACS) and being held October 21-24 in Barcelona, Spain.\n\n\tLogistical details for the poster presentation include:\n\n\tPoster PE6/4: AR-12, a Novel First in Class Host Cell Targeting Therapeutic Candidate with Potent Activity Against HIV Multidrug Resistant Strains in vitro\n\n\t\n\t\t\n\t\t\t\n\t\t\t\tFirst Author:\n\t\t\t\n\t\t\t\tStefan Proniuk, PhD\n\t\t\n\t\t\n\t\t\t\n\t\t\t\tDate, Time:\n\t\t\t\n\t\t\t\tWednesday, October 21 at 3:00 p.m. CEST through\n\t\t\n\t\t\n\t\t\t\n\t\t\t\t \n\t\t\t\n\t\t\t\tSaturday, October 24 at 12:00 p.m. CEST\n\t\t\n\t\t\n\t\t\t\n\t\t\t\tLocation: \n\t\t\t\n\t\t\t\tExhibition Area, Level 0\n\t\t\n\t\n\n\n\tAbout AR-12\n\n\tAR-12 is an orally-available small molecule. Data reported previously demonstrate that the AR-12 mechanism of action may include induction of host cell autophagy and inhibition of a number of protein chaperones. AR-12 has completed Phase 1 clinical trials in patients with cancer. AR-12 has been granted two orphan drug designations in Europe for the treatment of cryptococcosis and tularaemia. In addition, Arno also has the rights to a broad portfolio of compounds in the \"AR-12 series\", which have been demonstrated to have a broad spectrum antimicrobial activity. In addition, the anti-viral activity of AR-12 and various analogues against Ebola and other pathogens of biodefense interest is being evaluated under a Cooperative Research and Development Agreement (CRADA) Material Transfer Agreement with the US Army Medical Research Institute of Infectious Diseases (USAMRIID).\n\n\tAbout Arno Therapeutics\n\n\tArno Therapeutics is a clinical stage biopharmaceutical company developing innovative products for the treatment of cancer and other life threatening diseases.  Arno has exclusive worldwide rights to develop and market three innovative product candidates.  These compounds are in clinical or preclinical development as product candidates...